Related Experiment Video

Updated: Jul 28, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable

P J Casterella1, D J Kereiakes, S R Steinhubl

  • 1Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California, USA. pjc151@home.com

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|December 18, 2001
PubMed

Insights

This study found significant variability in how patients respond to abciximab during percutaneous coronary intervention (PCI). Many patients achieve effective platelet inhibition with less than the standard dose, suggesting personalized dosing may be beneficial.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Platelet aggregation is crucial in percutaneous coronary intervention (PCI).
  • Abciximab is an antiplatelet medication used during PCI to prevent thrombotic complications.
  • Optimizing abciximab dosing is essential for patient outcomes.

Purpose of the Study:

  • To evaluate the dose-response relationship of abciximab on platelet function in patients undergoing PCI.
  • To identify the percentage of patients achieving adequate platelet inhibition at different abciximab dose levels.

Main Methods:

  • A point-of-service platelet function assay was used in 85 patients.
  • Patients received incremental bolus doses of abciximab during PCI.
  • Platelet function was measured at 10-minute intervals during incremental dosing.

Main Results:

  • 40% of patients achieved >= 80% platelet inhibition with 50% of a standard abciximab bolus.
  • 87% of patients achieved >= 80% platelet inhibition with 75% of a standard abciximab bolus.
  • 95% of patients achieved >= 80% platelet inhibition with 100% of a standard abciximab bolus.
  • No significant associations were found between dose-response and patient factors like age, weight, or comorbidities.

Conclusions:

  • Significant interpatient variability exists in platelet function response to abciximab.
  • A substantial proportion of patients achieve high-level platelet inhibition with less than the standard abciximab dose.
  • These findings suggest potential for individualized abciximab dosing strategies in PCI.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...